X
KYMR icon

Xponance’s Kymera Therapeutics KYMR Stock Holding History

Xponance’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$707K Buy
6,162
+788
+15% +$67.7K ﹤0.01% 937
2026
Q1 		$448K Buy
5,374
+869
+19% +$68.8K ﹤0.01% 1062
2025
Q4 		$351K Buy
4,505
+522
+13% +$35.3K ﹤0.01% 1093
2025
Q3 		$225K Buy
+3,983
New +$180K ﹤0.01% 1302

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Xponance's KYMR Position: Q2 2026 in Review

Xponance increased its Kymera Therapeutics (KYMR) stake by 15% in Q2 2026, buying an estimated $67.7K and bringing the position to 6,162 shares worth $707K. The position accounts for ﹤0.01% of the portfolio, ranked #937.

Xponance first reported a position in KYMR in Q3 2025 and has held it in 4 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Xponance held 6,162 shares of Kymera Therapeutics worth $707K as of Q2 2026.
  • Xponance bought 788 Kymera Therapeutics shares in Q2 2026, an estimated $67.7K.
  • Kymera Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #937 holding.
  • Xponance first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.